SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.43% Passive Stake in Medicus Pharma Ltd.
Beneficial Ownership Report
Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a passive beneficial ownership of 9.43% in Medicus Pharma Ltd., totaling 1,266,000 common shares.
Summary
- Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership in Medicus Pharma Ltd.
- The Reporting Persons collectively own 1,266,000 common shares of Medicus Pharma Ltd.
- This ownership represents 9.43% of the company's common shares outstanding.
- The percentage is based on 13,428,561 shares outstanding as of April 15, 2025, as reported in Medicus Pharma Ltd.'s Form 10-K/A filed on April 30, 2025.
- Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of these shares.
- Steven Boyd, as the managing member of Armistice Capital, LLC, is deemed to beneficially own these securities.
- The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment. It is a neutral, compliance-driven filing.
Future Outlook
NA
Management Comments
- The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an investment firm in a publicly traded company, common within the financial industry for transparency regarding large holdings.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive ownership stake by an institutional investor, which can be viewed as a vote of confidence in the company's long-term prospects by a large holder.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement. |
| 04/15/2025 | Date as of which 13,428,561 shares outstanding were reported by the Issuer. |
| 04/30/2025 | Date Medicus Pharma Ltd. filed its Form 10-K/A with the SEC, reporting shares outstanding. |
| 05/15/2025 | Date the Schedule 13G was signed and filed by Armistice Capital, LLC and Steven Boyd. |
Keywords
Medicus Pharma Ltd., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Shares, Investment Management, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.